Purification and reaction mechanisms of the primary inhibitor of plasmin from human plasma.
The primary inhibitor of plasmin in human plasma was purified by a four-step procedure involving fractional (NH(4))(2)SO(4) precipitation, ion-exchange chromatography on a column of DEAE-Sepharose CL-6B and affinity chromatography on both a plasminogen-CH-Sepharose 4B column and a column of 6-aminohexanoic acid covalently coupled through the carboxylate function to AH-Sepharose 4B. No impurities in the final preparation could be detected when tested by immunoelectrophoresis against a range of specific antisera or against rabbit anti-human serum. On polyacrylamide-gel electrophoresis the inhibitor preparation showed a single band. The dissociation constant for the inhibitor-plasminogen complex was determined to be approx. 3mum at pH7.8. The reactions of the inhibitor with human plasmin and with bovine trypsin were studied. Comparison of the results obtained confirms the hypothesis previously presented, namely that the reaction of the inhibitor with plasmin involves at least two steps, the initial rapid formation of an enzyme-inhibitor complex followed by a slow irreversible transition to another complex. The results also indicate that the reaction of the inhibitor with trypsin involves just a single, irreversible step, so that this reaction seems to be less complicated than that of the inhibitor with plasmin. The ways in which 6-aminohexanoic acid influences the reactions were studied. The same value for the dissociation constant (approx. 26mum) for 6-aminohexanoic acid is obtained for both its effect on the reaction of the inhibitor with trypsin and for competitive inhibition of trypsin. The inhibitory effect of 6-aminohexanoic acid thus seems to be due to its blocking of the active site of trypsin. In contrast with this, the inhibitory effects of l-lysine and 6-aminohexanoic acid on the inhibitor-plasmin reaction occur at concentrations much too low to affect the active site of plasmin. The possible dependence of the reaction of the inhibitor with plasmin on a second site(s) on plasmin is discussed.
D015119:Aminocaproic Acid / Q000494:pharmacology; D001665:Binding Sites; D001798:Blood Proteins / Q000302:isolation & purification*; D004791:Enzyme Inhibitors / Q000097:blood / Q000302:isolation & purification; D005341:Fibrinolysin / Q000037:antagonists & inhibitors*; D006801:Humans; D007700:Kinetics; D008722:Methods; D010958:Plasminogen / Q000494:pharmacology; D014361:Trypsin Inhibitors
D001798:Blood Proteins; D004791:Enzyme Inhibitors; D014361:Trypsin Inhibitors; D010958:Plasminogen; D005341:Fibrinolysin; D015119:Aminocaproic Acid